The Nano-War Against Complement Proteins
- 10 September 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 23 (5), 1-8
- https://doi.org/10.1208/s12248-021-00630-9
Abstract
Targeted drug delivery and nanomedicine hold the potential promise of delivering drugs solely to target organs or cell types, thus decreasing off-target side effects and improving efficacy. However, nano-scale drug carriers face several barriers to this goal, with one of the most formidable being the complement cascade. Complement proteins, especially C3, opsonize not just the microbes they evolved to contain, but also nanocarriers. This results in multiple problems, including marking the nanocarriers for clearance by leukocytes, likely fouling of the targeting moieties on nanocarriers, and release of toxins which produce deleterious local and systemic effects. Here, we review how complement achieves its blockade of nanomedicine, which nanocarrier materials properties best avoid complement, and current and future strategies to control complement to unleash nanomedicine’s potential. Graphical abstractKeywords
This publication has 38 references indexed in Scilit:
- The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplificationMolecular Immunology, 2009
- Complement evasion strategies of pathogens—Acquisition of inhibitors and beyondMolecular Immunology, 2009
- Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearanceBiomaterials, 2009
- The introduction of ‘chemotherapy’ using arsphenamine – the first magic bulletJournal of the Royal Society of Medicine, 2009
- Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer TumorsClinical Cancer Research, 2005
- ComplementThe New England Journal of Medicine, 2001
- Liposome-induced and complement-mediated cardiopulmonary distress in pigs as a model of pseudo-allergic reactions to liposomal drugsMolecular Immunology, 1998
- Interaction of Serum Components with Poly(methylmethacrylate) Nanoparticles and the Resulting Body Distribution after Intravenous Injection in RatsJournal of Drug Targeting, 1993
- Preservation of antimyosin antibody activity after covalent coupling to liposomesBiochemical and Biophysical Research Communications, 1979
- Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscopeJournal of Molecular Biology, 1964